Company profile
LISATA THERAPEUTICS, INC.
NASDAQ:LSTABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PERIPHERAL BLOOD STEM/PROGENITOR CELLS, AUTOLOGOUS, CD34+, G-CSF MOBILIZED | phase2 | — | 4 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04614467 | phase2 | terminated | 2020-10-29 | 2022-09-28 | Lisata Therapeutics, Inc. | A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction |
| NCT05712356 | phase2 | terminated | 2023-05-13 | 2026-04-05 | Lisata Therapeutics, Inc. | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |
| NCT00300053 | phase2 | completed | 2006-04-01 | 2008-03-01 | Lisata Therapeutics, Inc. | ACT34-CMI -- Adult Autologous CD34+ Cells |
| NCT01875653 | phase3 | terminated | 2014-10-01 | 2016-01-01 | Lisata Therapeutics, Inc. | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma |
| NCT03517176 | phase1 | completed | 2018-07-31 | 2020-06-19 | Lisata Therapeutics, Inc. | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer |
FDA applications (0)
No records yet.